case_images: PMC11785699_01
case_images: Contrast-enhanced computed tomography upon admission to our hospital
case_images: 12328_2024_2062_Fig1_HTML.jpg
case_images: PMC11785699_01_12328_2024_2062_Fig1_HTML.jpg
case_images: Fig1
case_images: Contrast-enhanced CT revealed an HCC with a maximum diameter of 10 cm centered on hepatic segments 5 and 8, with a peritoneal dissemination nodule measuring 22 mm in maximum diameter near the hepatoduodenal ligament and a maximum diameter of 35 mm near the omentum (Fig. 1).
case_images: Changes in contrast-enhanced computed tomography image after treatment in our hospital
case_images: 12328_2024_2062_Fig2_HTML.jpg
case_images: PMC11785699_01_12328_2024_2062_Fig2_HTML.jpg
case_images: Fig2
case_images: Post-treatment CT showed attenuation of enhancement in the intrahepatic lesions; however, intrahepatic lesions and peritoneal dissemination progressed (Fig. 2a). There were no obvious treatment-related adverse events; however, progression of all lesions was observed on contrast-enhanced CT after the administration of the second course of atezolizumab and bevacizumab on December, 2020 (Fig. 2b). Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) were observed 1 week after the start of cabozantinib treatment (Table 1). Contrast-enhanced CT showed attenuation of enhancement in the liver lesion and peritoneal dissemination (Fig. 2c), and tumor markers (including AFP and DCP) decreased (Fig. 3, Table 2). Contrast-enhanced CT showed attenuation of blood flow in the intrahepatic lesion and peritoneal dissemination nodules, and the tumor size decreased, leading to a diagnosis of CR according to mRECIST (Fig. 2d).